(Q46093696)

English

Effect of oral cladribine on time to conversion to clinically definite multiple sclerosis in patients with a first demyelinating event (ORACLE MS): a phase 3 randomised trial

scientific article published on 4 February 2014

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

19 December 2017

http://europepmc.org/abstract/MED/24502830

Effect of oral cladribine on time to conversion to clinically definite multiple sclerosis in patients with a first demyelinating event (ORACLE MS): a phase 3 randomised trial (English)

1 reference

Europe PubMed Central

19 December 2017

http://europepmc.org/abstract/MED/24502830

phase III clinical trial

0 references

multiple sclerosis

0 references

Hans-Peter Hartung

6

object named as

Hans-Peter Hartung

1 reference

Europe PubMed Central

19 December 2017

2

object named as

Giancarlo Comi

1 reference

Europe PubMed Central

19 December 2017

3

object named as

Bruce A C Cree

1 reference

Europe PubMed Central

19 December 2017

http://europepmc.org/abstract/MED/24502830

author name string

Thomas P Leist

1

1 reference

Europe PubMed Central

19 December 2017

http://europepmc.org/abstract/MED/24502830

Patricia K Coyle

4

1 reference

Europe PubMed Central

19 December 2017

http://europepmc.org/abstract/MED/24502830

Mark S Freedman

5

1 reference

Europe PubMed Central

19 December 2017

http://europepmc.org/abstract/MED/24502830

Patrick Vermersch

7

1 reference

Europe PubMed Central

19 December 2017

http://europepmc.org/abstract/MED/24502830

Florence Casset-Semanaz

8

1 reference

Europe PubMed Central

19 December 2017

http://europepmc.org/abstract/MED/24502830

Matthew Scaramozza

9

1 reference

Europe PubMed Central

19 December 2017

http://europepmc.org/abstract/MED/24502830

oral cladribine for early MS (ORACLE MS) Study Group

10

1 reference

Europe PubMed Central

19 December 2017

http://europepmc.org/abstract/MED/24502830

publication date

4 February 2014

1 reference

Europe PubMed Central

19 December 2017

http://europepmc.org/abstract/MED/24502830

Lancet Neurology

1 reference

Europe PubMed Central

19 December 2017

http://europepmc.org/abstract/MED/24502830

13

1 reference

Europe PubMed Central

19 December 2017

http://europepmc.org/abstract/MED/24502830

3

1 reference

Europe PubMed Central

19 December 2017

http://europepmc.org/abstract/MED/24502830

257-267

1 reference

Europe PubMed Central

19 December 2017

http://europepmc.org/abstract/MED/24502830

Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970005-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970005-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970005-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Comparison of two dosing frequencies of subcutaneous interferon beta-1a in patients with a first clinical demyelinating event suggestive of multiple sclerosis (REFLEX): a phase 3 randomised controlled trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970005-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970005-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Effect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis: a 3-year follow-up analysis of the BENEFIT study

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970005-5

7 January 2021

based on heuristic

inferred from DOI database lookup

The role of CD4 T cells in the pathogenesis of multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970005-5

7 January 2021

based on heuristic

inferred from DOI database lookup

B cells and multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970005-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Immunotherapeutic approaches in MS: update on pathophysiology and emerging agents or strategies 2006.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970005-5

7 January 2021

based on heuristic

inferred from DOI database lookup

A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970005-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970005-5

7 January 2021

based on heuristic

inferred from DOI database lookup

New diagnostic criteria for multiple sclerosis: guidelines for research protocols

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970005-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970005-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Cladribine: mode of action and implications for treatment of multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970005-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Interferon beta 1-b in verbal memory functioning of patients with relapsing-remitting multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970005-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Recombinant interferon beta or glatiramer acetate for delaying conversion of the first demyelinating event to multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970005-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S1474-4422(14)70005-5

1 reference

Europe PubMed Central

19 December 2017

http://europepmc.org/abstract/MED/24502830

1 reference

Europe PubMed Central

19 December 2017

http://europepmc.org/abstract/MED/24502830

reason for deprecated rank

incorrect identifier value

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q46093696&oldid=2091597401"